NefIgArd
Nefecon in Patients with Primary IgA Nephropathy
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.
N
364
Schéma
Phase 3 double-blind RCT
Critère
Time-weighted eGFR over 2 years
Pertinence
2
Résultat+5.1 mL/min/1.73m² versus placebo (p<0.001); proteinuria reduced 41%.
Lafayette R, et al. Lancet. 2023;402(10405):859-870. 10.1016/S0140-6736(23)01554-4
Discussion et critique
Led to full FDA approval of Tarpeyo; off-drug follow-up and steroid-type adverse effects temper enthusiasm.